For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Trial Profile

For men with metastatic prostate cancer refractory to hormonal and chemotherapy, what is the efficacy and toxicity of radionuclide therapy with Lutetium-177 PSMA

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs PSMA 617 (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Acronyms LuPSMA Trial
  • Most Recent Events

    • 10 Oct 2017 New trial record
    • 02 Oct 2017 According to an Endocyte media release,updated results from the study are expected to be presented in 2018.
    • 02 Oct 2017 According to an Endocyte media release, this trial has subsequently been expanded to 50 subjects from the original 30.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top